Search bioRxiv⌕ Search

Biology subjects

Shibahara, D.

Publications and source records attributed to Shibahara, D..

2 recordsLinked to original sources

Inflammatory signaling drives SQSTM1-dependent suppression of interferon-γ-induced MHC class I

An immune-inflamed tumor microenvironment features interferon-{gamma} (IFN-{gamma}) and inflammatory cytokines, yet how cancer cells integrate these opposing signals to regulate immunogenicity remains poorly understood. Here, we investigated the effect of interleukin-1{beta} (IL-1{beta}) on IFN-{gamma}-induced major histocompatibility complex class I (MHC-I) expression in non-small cell lung cancer (NSCLC) cells. IL-1{beta} suppressed IFN-{gamma}-induced surface MHC-I expression despite preserved or enhanced expression of antigen presentation-related genes, indicating post-transcriptional regulation. This effect emerged 12-24 h after stimulation and accompanied accelerated MHC-I turnover without altering total protein abundance. RNA sequencing identified selective induction of autophagy-related genes under combined IFN-{gamma} and IL-1{beta} stimulation. Immunofluorescence and biochemical analyses demonstrated MHC-I redistribution to autophagosome-lysosome compartments. Mechanistically, the selective autophagy receptor SQSTM1 associated with MHC-I and was required for its surface downregulation, whereas NBR1 depletion and autophagy or lysosomal inhibition failed to restore MHC-I expression, indicating a nonredundant role for SQSTM1. These findings identify post-translational MHC-I trafficking as an underappreciated regulatory layer linking inflammatory signaling to the canonical IFN-{gamma}-MHC-I axis and reveal an SQSTM1-dependent mechanism controlling MHC-I surface availability in immune-inflamed tumors.

immunology↗

Spatial dynamics of the tumor microenvironment in emerging resistance to targeted therapy in EGFR-mutated NSCLC

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide therapeutic benefit in EGFR mutation-positive non-small cell lung cancer, but some individuals develop early resistance. We performed spatial transcriptomics analysis of pre- and posttreatment tumor samples from the same patients to explore the underlying mechanisms of such early resistance. The proportion and activation of fibroblasts increased in association with the development of early resistance, whereas a distinct tumor cell cluster showed activation of tumor necrosis factor- signaling via the NF-{kappa}B pathway even before treatment. Also in the early resistance sample, specific tumor cell clusters interacted with immune and stromal cells. Immature tertiary lymphoid structures (TLSs) were enriched in the early resistance sample, whereas mature TLSs were observed in the long-term response sample. These findings implicate tumor heterogeneity and an inflammatory tumor microenvironment in early EGFR-TKI resistance, providing insight into potential therapeutic strategies to improve treatment outcomes.

cancer biology↗